Jyoti S. Mayadev, MD, Discusses Future Directions Within the Cervical Cancer Space

Video

Jyoti S. Mayadev, MD, indicated that future research for cervical cancer will be focused on combination immune checkpoint inhibitors and biomarker research.

At the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting, Jyoti S. Mayadev, MD, a radiation oncologist and professor of radiation medicine and applied sciences at the University of California, San Diego School of Medicine, spoke with CancerNetwork® about where future research efforts are likely to be focused within the cervical cancer space. In particular, Mayadev highlighted how combination immunotherapies and biomarker research will be areas of focus for this population.

Transcript:

We've seen that immunotherapy with cervical cancer has been efficacious and improved survival in the metastatic setting. There have been synergies with various checkpoint inhibitors, including dual checkpoint inhibition—tyrosine kinase inhibitors [TKIs] and immunotherapy synergy. There have been new developments in terms of LAG-3 [inhibitors]. We have a real opportunity with novel therapeutics in cervical cancer and combinations with immunotherapy and synergies that will be better elucidated with biomarker development and better prediction tools as to which patients will unfortunately succumb to their disease despite standard therapy. Those are the patients that we need to enrich our clinical trial patient population with.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Multidisciplinary collaboration may help in minimizing the treatment burden among patients with prostate cancer, according to Curtiland Deville Jr., MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Related Content